WRN and cancer: Genome-scale CRISPR/Cas9 screening of 324 cancer cell lines from 30 cancer types, developed to provide an effective portfolio of cancer drug targets, has recently identified Werner syndrome ATP-dependent helicase (WRN) as a new candidate synthetic lethal target in microsatellite instability tumors [91].